Iodopol

Sodium Iodide (131I), the active ingredient in Iodopol, is a radioisotope presented as a radiopharmaceutical for oral use. It is employed in the management of thyroid disorders, including hyperthyroidism, differentiated thyroid cancer, and for diagnostic imaging of thyroid tissue.

GNH USA supplies Iodopol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, sourcing the product from EU‑regulated manufacturers.

Iodopol is used in the treatment and diagnostic evaluation of thyroid‑related conditions.

- Hyperthyroidism: reduces excess thyroid hormone production by selectively destroying overactive thyroid cells. - Differentiated thyroid cancer: ablates residual thyroid tissue after surgery to improve disease control. - Thyroid imaging: provides functional imaging of thyroid tissue distribution for diagnostic assessment.

Iodopol may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach occurring shortly after dosing. - Neck discomfort: transient pain or tenderness in the thyroid region. - Taste alteration: temporary metallic or altered taste sensation. - Transient hypothyroidism: temporary reduction in thyroid hormone levels requiring monitoring.

Serious or Rare Side Effects: - Severe radiation thyroiditis: painful inflammation of the thyroid gland. - Bone marrow suppression: decreased blood cell production leading to anemia or infection risk. - Allergic reactions: rash, itching, or rare anaphylaxis. - Pulmonary fibrosis (rare): scarring of lung tissue in susceptible individuals.

When prescribing Iodopol, clinicians should observe several precautionary measures to ensure patient safety.

- Dose individualization: calculate activity based on patient weight, thyroid uptake and disease severity. - Pregnancy avoidance: contraindicated in pregnant women due to fetal radiation exposure. - Breastfeeding caution: advise cessation of nursing during and after treatment. - Renal function monitoring: adjust dose in impaired renal clearance. - Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture and light.

Iodopol can interact with other agents that affect iodine metabolism or radiation sensitivity.

Major Interactions (Avoid): - Thyroid hormone replacement: may reduce therapeutic efficacy; adjust timing. - Antithyroid drugs (e.g., methimazole, propylthiouracil): can interfere with iodine uptake. - Lithium: impairs iodine organification, diminishing treatment effect.

Moderate Interactions (Monitor Closely): - Amiodarone: high iodine content may alter uptake; monitor thyroid function. - Corticosteroids: may modify inflammatory response post‑therapy. - Chemotherapeutic agents causing bone marrow suppression: increase risk of hematologic toxicity.